Any way, even if it is approved there can be adverse reactions to the drug, which can lead to lawsuits. A few years back a man took prozac and killed someone in a prozac induced halucination. I don't know if there was a lawsuit in this case but there was tons of negative media coverage.
If you are looking for a the benfits of celexa go with wla. they not only have lipitor, rezulin and all the over the counter stuff i mentioned in my prior post, they also have 10 drug in the pipeline that's 9 more than FRX.
To see the wla pipeline drugs, go the message just above this.
something is wrong with your assumption of 10 drugs in Warner Lambert's pipeline, because let me tell you something. In the area of the pharma field that WLA competes in, 10 drugs gets you DIDDLY SQUAT. So, either you have the wrong figures, or if its true, then I feel sorry for WLA stockholders. Let me tell you whats typical among pharma companies's pipelines. PFE has over 60 drugs in the pipeline. AHP alone has over 66 drugs in the pipeline, and with MTC combined into it has over 110 products in the pipeline. Even the long considered DOG of the pharmas PNU, has over 50 drugs in the pipeline. 10 drugs is puny, pathetic, and nothing to write home over.
First of all, there is little chance that Celexa won't be approved. They would have never received an approvable letter in May if that was the case. Pfizer's Zeldox showed some kind of safety problem during their clinical trials, which is why they got this letter. Celexa has been marketed for years in Europe and has an excellent safety profile. I don't think it "induces hallucinations", either. By the way, for all of Prozac's negative press, it's still in the top five prescribed drugs. Speaking of negative press, Viagra gets plenty of it and it's still flying off of pharmacy shelves.
Secondly, if raw profits are what you're after, forget Forest and wla anyway and go with sure winners like Microsoft or Dell Computer.
Hey, I have a great idea. Everybody buy both Forest and wla and make jimmy a happy camper.
-> pregabalin, an anticonvulsant, in development for epilepsy, neuropathic pain and other CNS disorders. This compound is minimally metabolized, making drug interactions unlikely. By the end of the year, the company will have initiated more than 25 clinical efficacy studies of this compound. They include trials in epilepsy, diabetic neuropathy, post-hepatic neuropathy, social phobia, anxiety disorder and acute/chronic pain.
->igmesine, a novel antidepressant that has demonstrated efficacy in Phase II trials for the treatment of major depressive disorder. Its unique mode of action offers the potential for a more rapid onset of action than current therapies with a favorable side effect profile.
->zenarestat, an aldose reductase inhibitor for the treatment and prevention of diabetic neuropathy. Licensed from Fujisawa, the therapy was shown in Phase II trials to limit and even reverse the nerve damage caused by diabetes.
->Metaret (suramin), a treatment for hormone refractory prostate cancer. In clinical trials, Metaret appears to be an effective treatment for the condition, decreasing pain scores and pain medication needs, and producing clinically significant reductions of the tumor marker PSA (Prostatic Specific Antigen). An NDA was filed at the end of 1997.
->CelexaTM (citalopram), a selective serotonin reuptake inhibitor, for the treatment of depression. A new drug application for CelexaTM was submitted by Forest Laboratories, Inc. to the U.S. Food and Drug Administration in May 1997. Warner-Lambert entered into an agreement with Forest Laboratories in March to co-promote the drug.
->avasimibe (CI-1011), an ACAT inhibitor, which prevents the accumulation of atherosclerotic plaque and reduces total cholesterol levels. In pre-clinical models, CI-1011 demonstrated a regression of arterial lesions. In addition, effective ACAT inhibitors may reduce total cholesterol levels by decreasing absorption of dietary cholesterol and reducing hepatic VLDL secretion. Phase III trials are expected to begin within a year.
->CI-1004, an anti-inflammatory that works by dual inhibition. It inhibits 5-lipoxygenase, the enzyme responsible for leukotrines, and it inhibits the cyclooxygenase, COX-2. This dual mechanism of action may provide advantages over COX-2 inhibition alone as a result of enhanced anti-inflammatory efficacy. CI-1004 could potentially have the GI safety of the new COX-2 agents with improved efficacy over current NSAIDS. Phase II trials for rheumatoid arthritis and osteoarthritis are expected to begin this year.
->CI-1001, (ethinyl estradiol/norethindrone acetate) an intravaginal ring, provides contraception for up to three months. A phase II trial showed good cycle control with excellent patient tolerance and acceptance. Phase III trials in both the U.S. and overseas are expected to begin in early 1999.
->FemHRT (ethinyl estradiol/norethindrone acetate) is a combination estrogen progestin hormone replacement therapy for use in treating osteoporosis and perimenopausal symptoms. The NDA is expected to be submitted in the U.S. within the next 12 months.
->clinafloxacin, a new generation quinolone anti-infective. This compound is effective against highly virulent bacteria, including those that are resistant to the most potent
drugs now available. The compound, for which oral and injectible forms are planned, will be for hospital use. An NDA is expected to be submitted later this year.
Those so called 10 products in WLA pipeline are either in advanced clinical development or are awaiting approval. Its not the entire pipeline. WLA entire pipeline i'm guessing is around 40-50 products. And FRX doesn't have only 1 drug in the pipeline. They have Celexa, awaiting approval for an Alzheimer's drug, and they've recently in-licensed 3 more compounds from HD Lundbeck. Other than those, I'm sure they've got more to show for their R&D spending as opposed to the 1 drug you believe them to have. Look a little closer next time JIMMY, maybe you'll get the right information.